Lung Cancers Today
Advertisement
The study examined the effectiveness of various interventions aimed at increasing lung cancer screening uptake rates.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Dr. Conkling shared his research insights on PD-L1 testing practices for mNSCLC within US community oncology settings.
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
The panel discussed advancements in the field, including results from a study of lurbinectedin plus atezolizumab for SCLC.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about oncology referrals in NSCLC.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about recent NSCLC innovations.
Sanjay Juneja, MD, directed a discussion with Dr. Liu, Dr. Das, and Dr. Singhi on key updates in the field of NSCLC.
Jessica Bauman, MD, discusses a new analysis of the REACH PC study that she presented at ASCO 2025.
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
The approval is for adults who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Dr. Sen explains how her team identified targetable genes that define immune suppression in small cell lung cancer.
Stephen Liu, MD, shares his insights on the recent approval, the data behind it, and what the future may hold.
Jennifer Carlisle, MD, shares her institution’s experience with outpatient administration of the bispecific T-cell ...
Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic.
Sanjay Juneja, MD, was joined by lung cancer experts Dr. Liu, Dr. Das, and Dr. Singhi to discuss critical ASCO 2025 data.
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.